Hillmen, P. (2009). The role of alemtuzumab in the treatment of chronic lymphocytic leukemia (CLL) and the achievement of minimal residual disease negativity in relapsed/refractory CLL. Hematology Meeting Reports (formerly Haematologica Reports), 1(2). https://doi.org/10.4081/hmr.v1i2.226